Top

Published in:

01-12-2022 | Budesonide | Study protocol

Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Authors: Qing Kong, Yuxue Cao, Zhen Gao, Jing Sun, Hongying Zhang, Yijie Du, Yubao Lv, Sihan Zhou, Zihui Tang, Baojun Liu, Jingcheng Dong

Published in: Trials | Issue 1/2022

Abstract

Background

Inhaled glucocorticoid corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and other drugs have limited therapeutic effects on COPD with significant individual differences. Traditional Chinese medicine (TCM)-modified Bushen Yiqi formula (MBYF) demonstrates advantages in COPD management in China. This study aims to evaluate the efficacy and safety of MBYF as an add-on to budesonide/formoterol in COPD patients and confirm the related genes affecting the therapeutic effect in the treatment of COPD.

Methods

In this multicentre, randomised, double-blind, placebo-controlled, parallel-group study, eligible patients with COPD will randomly receive a 360-day placebo or MBYF as an adjuvant to budesonide/formoterol in a 1:1 ratio and be followed up with every 2 months. The primary outcomes will be the frequency, times, and severity of acute exacerbation of COPD (AECOPD), COPD assessment test (CAT) score, and pulmonary function tests (PFTs). The secondary outcomes will include the modified Medical Research Council (mMRC) dyspnoea scale, 6-min walking test (6MWT), BODE index, quantitative scores of syndromes classified in TCM, inflammation indices, and hypothalamic-pituitary-adrenaline (HPA) axis function. We will also test the genotype to determine the relationship between drugs and efficacy. All the data will be recorded in case report forms (CRFs) and analysed by SPSS V.20.0.

Discussion

A randomized clinical trial design to evaluate the efficacy and safety of MBYF in COPD is described. The results will provide evidence for the combination therapy of modern medicine and TCM medicine, and individual therapy for COPD.Trial registration.

Trial registration

ID: ChiCTR1900026124, Prospective registration.

Available only for authorised users

The top 10 causes of death 2018 [Available from: https://www.who.int/zh/news-room/fact-sheets/detail/the-top-10-causes-of-death.

Burden of Chronic Obstructive Pulmonary Disease: World Health Organization; 2019 [Available from: https://www.who.int/respiratory/copd/burden/en/.

Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health CPH study): a national cross-sectional study. Lancet. 2018;391(10131):1706–17. https://doi.org/10.1016/S0140-6736(18)30841-9.CrossRefPubMed

Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–58. https://doi.org/10.1016/S0140-6736(19)30427-1.CrossRefPubMedPubMedCentral

Dong F, Ren X, Huang K, Wang Y, Jiao J, Yang T. Development and validation of risk prediction model for in-hospital mortality among patients hospitalized with acute exacerbation chronic obstructive pulmonary disease between 2015 and 2019. Front Med. 2021;8:630870. https://doi.org/10.3389/fmed.2021.630870.CrossRef

Silverman EK. Genetics of COPD. Annu Rev Physiol. 2020;82(1):413–31. https://doi.org/10.1146/annurev-physiol-021317-121224.CrossRefPubMed

Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–40. https://doi.org/10.1016/S0140-6736(17)31222-9.CrossRefPubMed

Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17–itc32.CrossRefPubMed

Vanfleteren L, Spruit MA, Wouters EFM, Franssen FME. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911–24. https://doi.org/10.1016/S2213-2600(16)00097-7.CrossRefPubMed

10.

Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85. https://doi.org/10.1183/09031936.00128008.CrossRefPubMed

11.

Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(1):24–36. https://doi.org/10.1164/rccm.202009-3533SO.CrossRefPubMedPubMedCentral

12.

Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18(7):454–66. https://doi.org/10.1038/s41577-018-0006-6.CrossRefPubMed

13.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5). https://doi.org/10.1183/13993003.00164-2019.

14.

Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. https://doi.org/10.1183/09031936.03.00031402.CrossRefPubMed

15.

Leitao Filho FS, Takiguchi H, Akata K, Ra SW, Moon JY, Kim HK, et al. Effects of inhaled corticosteroid/long-acting β(2)-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a Randomized Controlled Clinical Trial (DISARM). Am J Respir Crit Care Med. 2021;204(10):1143–52. https://doi.org/10.1164/rccm.202102-0289OC.CrossRefPubMed

16.

Chang TY, Chien JY, Wu CH, Dong YH, Lin FJ. Comparative safety and effectiveness of inhaled corticosteroid and long-acting β(2)-agonist combinations in patients with COPD. Chest. 2020;157(5):1117–29. https://doi.org/10.1016/j.chest.2019.12.006.CrossRefPubMed

17.

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe. Eur Respir J. 2018;52(6):1801219.CrossRefPubMed

18.

Toogood JH. Side effects of inhaled corticosteroids. J Allergy Clin Immunol. 1998;102(5):705–13. https://doi.org/10.1016/S0091-6749(98)70007-7.CrossRefPubMed

19.

Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest. 2019;156(6):1092–110. https://doi.org/10.1016/j.chest.2019.06.036.CrossRefPubMed

20.

Wang CY, Lin YS, Wang YH, Lai CC, Wang HC, Chen L, et al. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists. Aging (Albany NY). 2019;11(17):6863–71. https://doi.org/10.18632/aging.102217.CrossRef

21.

Agustí A, Vogelmeier C, Faner R. COPD 2020: changes and challenges. Am J Physiol Lung Cell Mol Physiol. 2020;319(5):L879–l83. https://doi.org/10.1152/ajplung.00429.2020.CrossRefPubMed

22.

Meinke L, Chitkara R, Krishna G. Advances in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2007;8(1):23–37. https://doi.org/10.1517/14656566.8.1.23.CrossRefPubMed

23.

Haifeng W, Hailong Z, Jiansheng L, Xueqing Y, Suyun L, Bin L, et al. Effectiveness and safety of traditional Chinese medicine on stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Med. 2015;23(4):603–11. https://doi.org/10.1016/j.ctim.2015.06.015.CrossRefPubMed

24.

Ma JF, Zheng JP, Zhong NS, Bai CX, Wang HY, Du J, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chron Obstructive Pulm Dis. 2018;13:3107–14. https://doi.org/10.2147/COPD.S170555.CrossRef

25.

Jiansheng L, Haifeng W, Suyun L, Hailong Z, Xueqing Y, Xiaoyun Z, et al. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window. Complement Ther Med. 2016;29:109–15. https://doi.org/10.1016/j.ctim.2016.09.009.CrossRefPubMed

26.

Wang Y, Xu A. Zheng: A systems biology approach to diagnosis and treatments. Science. 2014;346(6216):S13–S5.

27.

Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting aging pathways in chronic obstructive pulmonary disease. Int J Mol Sci. 2020;21(18):6924.CrossRefPubMedCentral

28.

Wang GF, Liu BJ, Cao YX, Du YJ, Zhang HY, Luo QL, et al. Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial. Plos ONE. 2014;9(8):e103168.CrossRefPubMedPubMedCentral

29.

Huang M, Wu J, Dong J. Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4(+) type 9 helper T cells and the VIP-VPAC2 signalling pathway. Pharm Biol. 2021;59(1):1216–32. https://doi.org/10.1080/13880209.2021.1970198.CrossRefPubMedPubMedCentral

30.

Qin J, Wuniqiemu T, Wei Y, Teng F, Cui J, Sun J, et al. Proteomics analysis reveals suppression of IL-17 signaling pathways contributed to the therapeutic effects of Jia-Wei Bu-Shen-Yi-Qi formula in a murine asthma model. Phytomedicine. 2021;153803:153803. https://doi.org/10.1016/j.phymed.2021.153803.CrossRef

31.

Kong Q, Mo S, Wang W, Tang Z, Wei Y, Du Y, et al. Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial. Trials. 2020;21(1):760. https://doi.org/10.1186/s13063-020-04669-5.CrossRefPubMedPubMedCentral

32.

Wei Y, Lyu Y, Li M, Luo Q, Sun J, Liu F, et al. Comparison of effect of granules and herbs of Bu-Shen-Yi-Qi-Tang on airway inflammation in asthmatic mice. Chin Med J. 2014;127(22):3957–62.PubMed

33.

Cui J, Xu F, Tang Z, Wang W, Hu LL, Yan C, et al. Bu-Shen-Yi-Qi formula ameliorates airway remodeling in murine chronic asthma by modulating airway inflammation and oxidative stress in the lung. Biomed Pharmacother. 2019;112:108694. https://doi.org/10.1016/j.biopha.2019.108694.CrossRefPubMed

34.

Wei Y, Luo QL, Sun J, Chen MX, Liu F, Dong JC. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. J Ethnopharmacol. 2015;164:368–77. https://doi.org/10.1016/j.jep.2015.01.016.CrossRefPubMed

35.

Luo QL, Nurahmat M, Li MH, Sun J, Chen MX, Liu F, et al. Pharmacological investigation of a HPLC/MS standardized three herbal extracts containing formulae (Bu-Shen-Yi-Qi-Tang) on airway inflammation and hypothalamic-pituitary-adrenal axis activity in asthmatic mice. Phytomedicine. 2014;21(11):1439–50. https://doi.org/10.1016/j.phymed.2014.06.006.CrossRefPubMed

36.

Sun X, Deng X, Cai W, Li W, Shen Z, Jiang T, et al. Icariin inhibits LPS-induced cell inflammatory response by promoting GRalpha nuclear translocation and upregulating GRalpha expression. Life Sci. 2018;195:33–43. https://doi.org/10.1016/j.lfs.2018.01.006.CrossRefPubMed

37.

Li L, Sun J, Xu C, Zhang H, Wu J, Liu B, et al. Icariin ameliorates cigarette smoke induced inflammatory responses via suppression of NF-kappaB and modulation of GR in vivo and in vitro. PLoS ONE. 2014;9(8):e102345. https://doi.org/10.1371/journal.pone.0102345.CrossRefPubMedPubMedCentral

38.

Zhou MQ, Zhuo LY, Cai C. Astragaloside IV inhibits cigarette smoke-induced pulmonary inflammation in mice. Inflammation. 2018;41(5):1671–80. https://doi.org/10.1007/s10753-018-0811-x.CrossRef

39.

Xu F, Lin J, Cui W, Kong Q, Li Q, Li L, et al. Scutellaria baicalensis attenuates airway remodeling via PI3K/Akt/NF-kappaB pathway in cigarette smoke mediated-COPD rats model. Evid Based Complement Alternat Med. 2018;2018:1281420–12. https://doi.org/10.1155/2018/1281420.CrossRefPubMedPubMedCentral

40.

Wang GF, Mohammadtursun N, Lv YB, Zhang HY, Sun J, Dong JC. Baicalin exerts anti-airway inflammation and anti-remodelling effects in severe stage rat model of chronic obstructive pulmonary disease. Evid Based Complement Altern Med. 2018;2018:7591348.

41.

MH L, AH L, HF L, HK K, TS L, YR K. Paeonol attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling. Mediat Inflamm. 2014;2014:651890.

42.

Lin JP, Xu F, Wang GF, Kong LW, Luo QL, Lv YB, et al. Paeoniflorin attenuated oxidative stress in rat COPD model induced by cigarette smoke. Evid Based Complement Altern Med. 2016;2016:1698379.

43.

König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine. Eur Respir J. 2017;50(4).

44.

Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(Suppl 2):S90–s105.PubMed

45.

Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2)1900651.

46.

McGeachie MJ, Wu AC, Chang HH, Lima JJ, Peters SP, Tantisira KG. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J. 2013;13(4):306–11. https://doi.org/10.1038/tpj.2012.15.CrossRefPubMed

47.

Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365(13):1173–83. https://doi.org/10.1056/NEJMoa0911353.CrossRefPubMedPubMedCentral

48.

Maitland-van der Zee AH, Raaijmakers JA. Variation at GLCCI1 and FCER2: one step closer to personalized asthma treatment. Pharmacogenomics. 2012;13(3):243–5. https://doi.org/10.2217/pgs.11.177.CrossRefPubMed

49.

Koster ES, Maitland-van der Zee AH, Tavendale R, Mukhopadhyay S, Vijverberg SJ, Raaijmakers JA, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy. 2011;66(12):1546–52. https://doi.org/10.1111/j.1398-9995.2011.02701.x.CrossRefPubMed

50.

Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (London, England). 2004;364(9444):1505–12.CrossRef

51.

Scott SA, Patel M, Martis S, Lubitz SA, van der Zee S, Yoo C, et al. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2. GGCX and CALU Pharmacogenomics. 2012;13(3):297–307. https://doi.org/10.2217/pgs.11.156.CrossRefPubMed

52.

O'Meara A, Boukouaci W, Robin M, Xhaard A, Fortier C, Marzais F, et al. GLCCI1 and glucocorticoid receptor genetic diversity and response to glucocorticoid-based treatment of graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(7):1246–50. https://doi.org/10.1016/j.bbmt.2015.03.015.CrossRefPubMed

53.

Izuhara Y, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Horiguchi T, et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy. 2014;69(5):668–73. https://doi.org/10.1111/all.12400.CrossRefPubMed

54.

Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, et al. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. Ann Intern Med. 2017;167(2):112–21. https://doi.org/10.7326/M16-2977.CrossRefPubMed

55.

Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. https://doi.org/10.7326/0003-4819-158-3-201302050-00583.CrossRefPubMedPubMedCentral

56.

Vickerstaff V, Ambler G, King M, Nazareth I, Omar RZ. Are multiple primary outcomes analysed appropriately in randomised controlled trials? A review. Contemp Clin Trials. 2015;45(Pt A):8–12.CrossRefPubMed

57.

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586. https://doi.org/10.1136/bmj.e7586.CrossRefPubMedPubMedCentral

Title: Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial
Authors: Qing Kong
Yuxue Cao
Zhen Gao
Jing Sun
Hongying Zhang
Yijie Du
Yubao Lv
Sihan Zhou
Zihui Tang
Baojun Liu
Jingcheng Dong
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Budesonide
Formoterol
Chronic Obstructive Lung Disease
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06057-7

At a glance: The STEP trials

Springer Medicine

Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Abstract

Background

Methods

Discussion

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

Study protocol for pragmatic trials of Internet-delivered guided and unguided cognitive behavior therapy for treating depression and anxiety in university students of two Latin American countries: the Yo Puedo Sentirme Bien study

DUbbing Language-therapy CINEma-based in Aphasia post-Stroke (DULCINEA): study protocol for a randomized crossover pilot trial

Oral vitamin D supplemental therapy to attain a desired serum 25-hydroxyvitamin D concentration in essential healthcare teams

A drug free solution for improving the quality of life of fibromyalgia patients (Fibrepik): study protocol of a multicenter, randomized, controlled effectiveness trial

PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trial

A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)